Inoue, Hiromasa
Milligan, Ki Lee
McConnon, Aine
Yoshisue, Hajime
Loefroth, Emil
McSharry, Martin
Yokoyama, Akihito
Ichinose, Masakazu
Article History
Received: 19 June 2020
Accepted: 3 February 2021
First Online: 2 March 2021
Competing interests
: Authors received no compensation related to development of the manuscript. H.I. reports grants from Boehringer-Ingelheim, Kyorin, MeijiSeikaPharma, Novartis, Ono, Taiho, and Teijin-Pharma and personal fees from Astellas, AstraZeneca, Boehringer-Ingelheim, GlaxoSmithKline, Kyorin, MerckSharp&Dohme, Novartis, Otsuka, and Sanofi, outside the submitted work. A.Y. reports personal fees from Boehringer-Ingelheim, AstraZeneca, and Novartis, outside the submitted work. M.I. reports nothing to disclose. K.L.M., A.M., H.Y., and E.L. are employees of Novartis. M.M. was an employee of Novartis Ireland Limited during the conduct of the study.